Company news

Aclaris Therapeutics, Inc. news in 2019

Aclaris Therapeutics, Inc.'s news releases, calls and decks from 2019, newest first.

View company

Aclaris Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Highlights and an Update on R&D Programs

November 6, 2019

Aclaris Therapeutics to Announce Third Quarter 2019 Financial Results on November 7, 2019

October 30, 2019

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Second Successful Pivotal Phase 3 Clinical Trial for the Treatment of Common Warts (THWART-1)

October 23, 2019

Aclaris Therapeutics Announces Divestiture of RHOFADE®

October 9, 2019

Aclaris Therapeutics Files Patent Infringement Lawsuit Against Taro Pharmaceuticals, Inc. for Filing an ANDA for a Generic Version of RHOFADE® (oxymetazoline hydrochloride) cream, 1%

October 7, 2019

Aclaris Therapeutics to Hold R&D Day

September 16, 2019

Aclaris Therapeutics’ A-101 45% Topical Solution Meets Primary and All Secondary Efficacy Endpoints in Pivotal Phase 3 Trial for the Treatment of Common Warts (THWART-2)

September 15, 2019

Decks in 2019